Clinical trials | EDC - IRCCS - Istituto Nazionale dei Tumori

INFO & CONTACTS: +39 02 2390 1

Search

Search

Follow us on

Clinical trials

Venetoclax and delayed rituximab with ibrutinib consolidation aiming at undetectable minimal residual disease (uMRD) in treatment-naïve patients with chronic lymphocytic leukemia (CLL)

Phase: Phase II-III clinical trials

Principal Investigator: Dott.ssa Farina Lucia

Main Facility: Ematologia

Drug: Venetoclax
VELOCITY-HNSCC Substudy-01: a phase 2 study of novel combination therapies in participants with previously untreatedrecurrent or metastatic head and neck squamous cell carcinoma regardless of PD-L1 expression status

Phase: Phase II-III clinical trials

Main Facility: Oncologia Medica 3 - Tumori testa-collo

Drug: Domvanalimab, Zimberelimab
Use of LOncastuximab Tesirine in patients with RElapsed/Refractory Diffuse Large B-Cell LYmphoma (DLBCL) or High Grade B-Cell Lymphoma (HGBCL) who have progressive disease after CAR T-cell treatment - LORELY

Phase: Phase II-III clinical trials

Principal Investigator: Prof. Corradini Paolo

Main Facility: Ematologia

Drug: Loncastuximab Tesirine
Targeting triple negative BREAst cancer metabolism with a combination of chemoimmunotherapy and a FASTing-like approach in the preoperative setting: the BREAKFAST 2 trial.

Phase: Phase II-III clinical trials

Principal Investigator: Prof. De Braud Filippo

Main Facility: Oncologia Medica 1

Drug: Paclitaxel + Carboplatino + Pembrolizumab
Doxorubicina o Epirubicina + Ciclofosfamide + Pembrolizumab
SUNRAY-01, A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First- Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizum

Phase: Phase II-III clinical trials

Main Facility: Thoracic Oncology Unit

Drug: Pembrolizumab, Olomorasib, Pemetrexed, Carboplatino, Cispatino
Restoring sensitivity to immunotherapy in advanced triple negative breast cancer exploiting ceralasertib priming followed by combined durvalumab/nab-paclitaxel: the Atribrave trial

Phase: Phase II-III clinical trials

Main Facility: Oncologia Medica 1

Drug: Ceralasertib
Durvalumab
Nab-Paclitaxel
Randomized, Open-label, Multicenter, Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants with Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NS

Phase: Phase II-III clinical trials

Main Facility: Thoracic Oncology Unit

Drug: Repotrectinib
Crizotinib
Prospective, multicenter, open-label clinical study to evaluate the efficacy and safety of TheraSphere™ followed by Durvalumab (Imfinzi®) with Tremelimumab (Imjudo®) for hepatocellular carcinoma (HCC)
Study short tit

Phase: Phase II-III clinical trials

Main Facility: Oncologic Surgery 1 – Hepato-Gastro-Pancreatic and Liver Transplantation

Drug: TheraSphere™ followed by Durvalumab and Tremelimumab
Pilot phase II study of Selinexor in combination with Ifosfamide, Etoposide and Dexamethasone (SIDE) in patients with relapsed or refractory Peripheral T-cell Lymphomas.

Phase: Phase II-III clinical trials

Principal Investigator: Prof. Corradini Paolo

Main Facility: Ematologia

Drug: Selinexor
Phase II study on trabectedin in adults and young adults HEY1-NOCA2 positive skeletal and extra-skeletal mesenchymal chondrosarcoma (MCS)

Phase: Phase II-III clinical trials

Main Facility: Oncologia Medica 2

Drug: Trabectedina
Phase I-II prospective trial, multicenter, open label, exploring the combination of Trabectedin plus RAdiotherapy in Soft Tissue Sarcoma patients

Phase: Phase II-III clinical trials

Principal Investigator: Dr. Gronchi Alessandro

Main Facility: General Surgery 7 – Sarcomas

Drug: Trabectedin combined with radiation therapy.
Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator’s Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma (TEBE-AM)

Phase: Phase II-III clinical trials

Main Facility: Oncologia Medica 1 - Unità Oncologia Medica Melanomi

Drug: Tebentafusp, Pembrolizumab
Neoadjuvant pembrolizumab plus chemotherapy in locally advanced sinonasal carcinoma (NeoPeSino)

Phase: Phase II-III clinical trials

Main Facility: Oncologia Medica 3 - Tumori testa-collo

Drug: Pembrolizumab
IDE196 (DAROVASERTIB) in combination with crizotinib versus investigator’s choice of treatment as first-line therapy in HLA-A2 negative metastatic uveal melanoma (DAR-UM-2)

Phase: Phase II-III clinical trials

Main Facility: Oncologia Medica 1 - Unità Oncologia Medica Melanomi

Drug: Darovasertib, Crizotinib
Nivolumab, Ipilimumab, Pembrolizumab, Dacarbazina
FASTing-like approach to improve the efficacy of maintenance IMMunotherapy in Extensive-stage small cell lung cancer patients not progressing on chemoimmunotherapy induction: the FASTIMMUNE trial.

Phase: Phase II-III clinical trials

Main Facility: Oncologia Medica 1

Drug: Atezolizumab
Efficacy and safety of frontline tislelizumab in patients with de novo Hodgkin lymphoma unsuitable for standard frontline chemotherapy: a phase II, open-label study.

Phase: Phase II-III clinical trials

Principal Investigator: Dott.ssa Rusconi Chiara

Main Facility: Ematologia

Drug: Tislelizumab (BGB-A317)
Consolidation with ADCT-402 (loncastuximab tesirine) after a short course of immunochemotherapy: a phase II study in BTKi-treated (or BTKi intolerant) Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) patients

Phase: Phase II-III clinical trials

Principal Investigator: Prof. Corradini Paolo

Main Facility: Ematologia

Drug: ADCT-402 (loncastuximab tesirine)
Circulating microRNAs to choose the IO strategy in PD-L1≥50% NSCLC patients: the Ark clinical trial

Phase: Phase II-III clinical trials

Main Facility: Thoracic Oncology Unit

Drug: Pembrolizumab

Chemoterapy:
-paclitaxel+cisplatin or carboplatin
-pemetrexed + cisplatin or carboplatin
Basket of Baskets: A Modular, Open-label, Phase II, Multicentre Study To Evaluate Targeted Agents in Molecularly Selected Populations With Advanced Solid Tumours.

Phase: Phase II-III clinical trials

Principal Investigator: Prof. De Braud Filippo

Main Facility: Oncologia Medica 1

Drug: Atezolizumab, Futibatinib, Amivantamab
An open-label, randomized phase III trial comparing local radiotherapy alone or combined with Obinutuzumab in early stage Follicular Lymphoma: the GAZEBO Trial from the Fondazione Italiana Linfomi

Phase: Phase II-III clinical trials

Principal Investigator: Prof. Corradini Paolo

Main Facility: Ematologia

Drug: Obinutuzumab